Authors

Latest:

Recommendations For Future Clinical Trials in R/R MM

Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).

Jamie Myers, PhD, RN

Latest:

Jamie Myers Describes the Design of Her CRCI Study

Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study

Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center

Latest:

The Future of Myeloproliferative Neoplasm Treatment

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Jamile M. Shammo, MD, Rush University Medical Center

Jamile Shammo, MD

Jamile M. Shammo, MD, is a professor of medicine (hematology and oncology), as well as the Dr. Marjorie C. Barnett – Dr. Hau C. Kwaan Professor at Northwestern University’s Feinberg School of Medicine

Latest:

Dr Shammo on Future Research Investigating Combination Regimens in Myelofibrosis

Jamile M. Shammo, MD, discusses future directions for investigating JAK inhibitor–based combination regimens in transfusion-dependent myelofibrosis.

Jan A. Burger, MD, PhD

Latest:

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Jan Burger, MD, PhD, The University of Texas MD Anderson Cancer Center

Jan Poleszczuk, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Jan S. Lewin, PhD

Latest:

The Impact of Lymphedema in Patients With Head and Neck Cancer

Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.

Janakiraman Subramanian, MD

Latest:

Dr. Subramanian on the Current Standard of Care in Stage III NSCLC

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Jane de Lartigue

Latest:

Next Steps for KRAS Inhibitors Focus on Tackling Resistance

The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C–mutant non–small cell lung cancer marks a milestone for cancer therapy.

Jane de Lartigue, PhD

Latest:

Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and Beyond

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

Jane E. Churpek, MD

Latest:

Dr. Churpek on Gene Mutations in Breast Cancer

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

Jane Hall, PhD

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Jane L. Meisel, MD

Latest:

Dr Meisel on the Mechanism of Action of Palazestrant in ER+, HER2– Breast Cancer

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

Jane M. Armer, RN, PhD

Latest:

Jane Armer on Lymphedema Symptoms and Treatments

Jane Armer director of ALFP Discusses Lymphedema Symptoms and Treatments

Jane N. Winter, MD

Latest:

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Jane Robertson, MD

Latest:

Dr. Robertson on Olaparib for Serous Ovarian Cancer

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Janet Hampton, RN, BS

Latest:

Janet Hampton Explains the Distress Thermometer Study

Janet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study

Janet Pregler, MD

Latest:

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.